Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOISYXETINE: Atomoxetine Effect on Learning Dynamics
NCT07239791Phase 1Recruiting
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Centre Hospitalier Sainte-Anne. Primary endpoint: Apparent Learning rate at Day 7. Started Nov 2025; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07239791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239791.